Biotech company Immutep (ASX:IMM) completed patient enrolment in the phase II portion of the AIPAC-003 clinical trial in metastatic breast cancer, according to a Thursday filing with the Australian Securities Exchange.
A total of 65 patients will be randomized to receive 30-milligram or 90-milligram doses of eftilagimod alpha in combination with paclitaxel to determine the optimal biological dose in line with the Food and Drug Administration's Project Optimus initiative, the filing said.
Immutep shares slid 2% in midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.